Navigation Links
Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Date:9/29/2010

WORCESTER, MA, Sept. 29 /PRNewswire-FirstCall/ - Generex Biotechnology Corporation (Nasdaq: GNBT), which is engaged in the research, development, and commercialization of drug delivery systems and technologies, today announced that its Board of Directors has appointed Mark Fletcher as Interim President and Chief Executive Officer effective immediately. The Board also appointed John P. Barratt, an independent director, to serve as Chairman of the Board.

Mr. Fletcher and Mr. Barratt succeed Anna E. Gluskin as Chief Executive Officer and President, and as Chairman, respectively. Ms. Gluskin continues as a director of the company. Mr. Fletcher has served as Generex's Executive Vice-President and General Counsel since joining the company in April 2003. Mr. Fletcher has practiced law since being admitted to the bar in Ontario, Canada, in 1991. Mr. Barratt has served on the Board since 2003, chairing the audit and compensation committees during this period of time.

In addition, the Board has appointed a special committee comprising its three independent directors. The special committee's responsibilities include immediately commencing a search to identify candidates to secure a permanent President and Chief Executive Officer.

"The directors recognize Ms. Gluskin's role as a co-founder of Generex and her contributions since becoming a director and President and CEO in 1997," said Mr. Barratt. "During the past 13 years, Generex has developed core technologies and products that we continue to believe will be the platform for future growth, profitability, and the creation of value for the company's shareholders.

"The Board has concluded, however, that Generex has reached a stage in its maturation where new senior management leadership is now needed for the company to capitalize more effectively on the opportunities that we believe are available to the company. We be
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Yongye Biotechnology International Retains CCG Investor Relations
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Announces Second Quarter Results
7. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
8. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
9. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
10. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
11. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... Systems Inc.,(Amex: PLC ) today announced that it ... dated September 17, 2008 from the Listing,Qualifications Department staff ... Company was not in compliance with Section 1003(a)(ii) of,the ... less,than $4,000,000 as of June 30, 2008, and it ...
... 18 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a ... anti-adhesion, drug delivery products and other,surgical implants, announced ... the,AdvaMed 2008 MedTech conference being held in Washington, ... and CEO of SyntheMed, is scheduled,to present on ...
... NOVATO, Calif., Sept. 18 BioMarin,Pharmaceutical Inc. (Nasdaq: ... article released by Bloomberg this morning. The article ... Chief Executive Officer of,BioMarin, held on September 17, ... is consistent with the,information previously released publicly:, ...
Cached Biology Technology:PLC Systems Receives Delisting Notice From American Stock Exchange 2SyntheMed To Present at the AdvaMed 2008 MedTech Conference 2BioMarin Corrects Information Included in Bloomberg Article 2BioMarin Corrects Information Included in Bloomberg Article 3
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... farming and the introduction of new crops relies on ... climate change. Basing their argument on evolutionary, ecological, genetic ... Eshkol School of Agriculture at the Hebrew University of ... not the likely cause of plant domestication in the ...
... products to save the planet? That,s the question behind ... for carbon-producing activities (such as flying), with the idea ... funding for alternative energy sources. At the same time, ... would be the most effective means through which the ...
... One year in to a project to save one of ... being revealed for the first time. Scientists from Queen ... discovered an astonishing variety of minute aquatic organisms, so small ... Stoke Fen nature reserve is coming under the microscope of ...
Cached Biology News:Stable climate and plant domestication linked 2You say offset, I say tax? Study suggests labels and political affiliation may affect preferences 2Scientists find amazing new pondlife on nature reserve 2
MpV17 transgene, murine homolog, glomerulosclerosis...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
8.1.1...
Biology Products: